New insider activity at Glaukos ( (GKOS) ) has taken place on February 23, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Glaukos director Aimee Weisner has executed a notable insider transaction, selling 15,000 shares of Glaukos stock in a deal valued at $1,760,761. This sale highlights a significant movement in insider holdings and may draw attention from investors tracking executive and director trading activity in Glaukos shares.
Recent Updates on GKOS stock
Glaukos shares reacted to record Q4 and 2025 revenues, with glaucoma growth led by iDose TR and management reaffirming 2026 sales guidance despite higher launch spending and a GAAP loss driven by a Photrexa‑to‑Epioxa impairment. Analysts raised price targets mainly because iDose TR’s ramp and new re‑administration label support longer‑term volume growth, while Epioxa is seen as a large, de‑risked opportunity expected to rebuild and exceed Photrexa volumes over time, underpinning confidence in durable double‑digit revenue expansion.
Spark’s Take on GKOS Stock
According to Spark, TipRanks’ AI Analyst, GKOS is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and negative operating cash flow) and an earnings-based valuation signal that reflects those losses. Offsetting these are a constructive technical backdrop (longer-term uptrend) and a notably strong earnings call with record sales, raised guidance, and meaningful product milestones, albeit with reimbursement and franchise-transition risks.
To see Spark’s full report on GKOS stock, click here.
More about Glaukos
YTD Price Performance: 3.71%
Average Trading Volume: 808,318
Technical Sentiment Signal: Strong Buy
Current Market Cap: $6.95B